Gram-Positive Bacterial Infections clinical trials
The registry lists 58 studies for Gram-Positive Bacterial Infections across more than 10 countries. 6 are recruiting or about to start. 26 of them are mainly about Gram-Positive Bacterial Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-05. Counting its 24 narrower conditions too, such as Tuberculosis: 3,354 studies, 522 open.
Get an email when these change. Save the Gram-Positive Bacterial Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (6) · Pfizer (6) · Cumberland Pharmaceuticals (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · Michael Hoelscher (2) · Kirby Institute (2) · Seres Therapeutics, Inc. (2) · Novartis (1)
What is being tested here
Drugs under test in Gram-Positive Bacterial Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 2 Gram-Positive Bacterial Infections studies recruiting now, 2 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 2 (100%) | 2 (100%) |
Across all 58 studies, recruiting or not: 22% stop at 75 or younger and 22% at 65; 29% take children; 5% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 58. Browse all 58 → or search them.
- Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial InfectionsNot yet recruitingNCT078585261 country
- Oritavancin for Treatment of Serious Cardiac InfectionsNot yet recruitingNCT07550595Phase 21 country
- Oritavancin for CIED Infections With MDR Gram-positive CocciNot yet recruitingNCT07013552Not applicable1 country
- Fosfomycin I.v. for Treatment of Severely Infected PatientsRecruitingNCT029799515 countries
- Model-informed Precision Dosing for LinezolidNot yet recruitingNCT06444802Phase 3
- Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung DiseaseRecruitingNCT058249881 country
- A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant WomenActive, not recruitingNCT06592586Phase 2/32 countries
- BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)CompletedNCT04044001Phase 1/21 country
- Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsCompletedNCT02134301Phase 11 country
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionTerminatedNCT06418711Phase 35 countries
- Clinical Decision Support Tool for Vancomycin Dosing in ChildrenCompletedNCT04911270Not applicable1 country
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedNCT03896685Phase 36 countries
- Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)TerminatedNCT02013141Phase 11 country
- TNP-2092 to Treat Acute Bacterial Skin and Skin Structure InfectionCompletedNCT03964493Phase 21 country
- Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive InfectionsCompletedNCT00501150Not applicable1 country
- Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient TransitionTerminatedNCT04847921Phase 2/31 country
- Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)Approved for marketingNCT02437500
- Dalbavancin Outpatient PilotWithdrawnNCT03982030Phase 4
- PanACEA Sutezolid Dose-finding and Combination EvaluationCompletedNCT03959566Phase 22 countries
- ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionCompletedNCT03183141Phase 32 countries
- Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionCompletedNCT03747497Phase 21 country
- The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.Status unknownNCT04917380
- Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)TerminatedNCT00638157Phase 41 country
- BARDA Securing Anthrax Immunity For the ElderlyCompletedNCT03518125Phase 21 country
- Controlled Human Infection for Vaccination Against Streptococcus PyogenesCompletedNCT03361163Phase 11 country
- Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard AntibioticsCompletedNCT00136292Phase 11 country
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)CompletedNCT02750761Phase 1
- Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic AntibioticsCompletedNCT01019395Phase 11 country
- Telavancin for Treatment of Uncomplicated Staphylococcus Aureus BacteremiaCompletedNCT00062647Phase 21 country
- Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)CompletedNCT00061633Phase 21 country
- Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)CompletedNCT00077675Phase 21 country
- Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA BacteremiaTerminatedNCT00695903Phase 21 country
- Evaluation of the Dosing Regimen of Vancomycin in Pediatric PatientsCompletedNCT035604401 country
- Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill PatientsStatus unknownNCT03438214Phase 41 country
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World SettingCompletedNCT031594031 country
- Risk Factors for Staphylococcus Aureus Surgical Site Infections in Orthopedic and Trauma SurgeryStatus unknownNCT030409601 country
- Early-Onset Sepsis Surveillance StudyCompletedNCT008743671 country
- Daptomycin for the Treatment of Infections Due to Gram-Positive BacteriaTerminatedNCT00055198Phase 3
- Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure InfectionsCompletedNCT00633152Phase 21 country
- Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. AureusCompletedNCT00093067Phase 3
- Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and InflammationTerminatedNCT008357831 country
- Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their OffspringsCompletedNCT01412801Phase 22 countries
- Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their OffspringsCompletedNCT01446289Phase 22 countries
- Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile InfectionsWithdrawnNCT01077245Phase 2
- Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)CompletedNCT00079976Phase 3
- Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized SubjectsCompletedNCT00081744Phase 3
- Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream InfectionsTerminatedNCT00108433Phase 37 countries
- Post Marketing Surveillance Study on LinezolidCompletedNCT01564758
- A Study of Ceftobiprole in Patients With Fever and Neutropenia.TerminatedNCT00529282Phase 3
- Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric PatientsTerminatedNCT00240747Phase 31 country